A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in adult subjects with intestinal failure-associated liver disease (IFALD) receivin...
Age: 18 years - 66+
Gender: All
Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
Tricuspid regurgitation (TR) is a public health problem: moderate / severe TR are common,
especially in ageing populations, and affect 4% of the population >75 years old, totaling
approximately 1.6 million in the US and 3 million in Europe. TR is associated with an
...
Age: 18 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver
for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
prese...
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids,
compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis
in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tol...
Age: 18 years - 66+
Gender: All
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,
randomized, controlled trial of immunosuppressive therapy for children with acute liver
failure. The study will determine if suppressing inflammatory responses with either
cortic...
Age: 1 year - 18 years
Gender: All
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticostero...
Age: Birth - 18 years
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Molecular Assessment and Profiling of Liver Transplant Recipients
The objective of this protocol is to conduct longitudinal and prospective studies of liver
transplant recipients, using a multimodality approach, akin to that used in kidney
transplantation. The primary aim will compare the clinical outcomes of LiverCare
post-tran...
Age: 12 years - 66+
Gender: All
Molecular Assessment and Profiling of Liver Transplant Recipients
The objective of this protocol is to conduct longitudinal and prospective studies of liver
transplant recipients, using a multimodality approach, akin to that used in kidney
transplantation. The primary aim will compare the clinical outcomes of LiverCare
post-tran...
Age: 12 years - 66+
Gender: All
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy
and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial
chemoembolization (TACE) or transarterial radioembolization (TARE) for the first-line
treatmen...
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver
transplantation as an option, even if controversial. In sicker recipients, LT results in
immediate survival, but poor medium-term survival rates in some studies. The scarcit...
Age: 18 - 80 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
Age: 18 - 80 years
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression
of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an
accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing l...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
FAST (Focused Abbreviated Screening Technique)-MRI Study
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated
Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for
screening of liver cancer. Blood markers will be evaluated to determine their corr...
Age: 18 years - 66+
Gender: All
NOLA (NeuWave Observational Liver Ablation) Registry
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
Age: 22 years - 66+
Gender: All
NOLA (NeuWave Observational Liver Ablation) Registry
This is a multicenter, observational registry that follows patients for a total of 5 years
from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation
System.
Age: 22 years - 66+
Gender: All
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic
performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Age: 18 - 75 years
Gender: All